Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK-SjS-1 phase 3 trial of deucravacitinib in active Sjögren's syndrome
MOH_2023-12-12_013102Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in Sjögren's syndrome (3 arms), sponsored by Bristol Myers Squibb. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
deucravacitinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2023-12-12_013102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-12_013102.